Clinical trials: Cholangiocarcinomas
Hepatocellular Carcinoma (HCC), Intrahepatic Cholangiocellular Carcinoma
Application of Super-Resolution Ultrasound (SRUS) in Liver Tumor
The macroscopic vascular supply of liver tumors varies considerably according to histological subtype, lesion size, and disease stage.
- Conditions
- Hepatocellular Carcinoma (HCC), Intrahepatic Cholangiocellular Carcinoma, Hepatic Hemangioma, Focal Nodular Hyperplasia
- Trial name
- SRUS (NCT07707661)
- Testing
- Perform super-resolution ultrasound imaging on the study population
- Volunteers
- 350 people, healthy volunteers welcome
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Metastatic Cholangiocarcinoma, Metastatic Hepatocellular Carcinoma
Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver
This phase II trial studies how well pevonedistat alone or in combination with chemotherapy (paclitaxel and carboplatin) works in treating patients with bile duct cancer of the liver.
- Conditions
- Metastatic Cholangiocarcinoma, Metastatic Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8
- Trial name
- NCT04175912
- Testing
- Carboplatin, Paclitaxel, Pevonedistat
- Where
- 419 sites in United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Liver Transection During Laparoscopic Liver Resection
Comparison of Hydro-dissection Versus Ultrasonic Aspirator in Division of Liver Parenchyma in Laparoscopic Resection
Background: until now, there is no agreement about the safest and feasible method for liver parenchyma transection during laparoscopic liver resection.
- Trial name
- LLS (NCT03208192)
- Testing
- liver transection during laparoscopic liver resection
- Where
- Russia
- Volunteers
- 68 people
- Sponsor
- Moscow Clinical Scientific Center
Cholangiocarcinoma, Gallbladder Carcinoma
Clinical Trial to Investigate the Efficacy of Treatment With Gemcitabine/Pazopanib in Patients With Biliary Tree Cancer
The purpose of this study is to determine whether gemcitabine and pazopanib are effective in the treatment of inoperable, locally advanced or metastatic biliary tree cancer (cholangiocarcinoma or gallbladder carcinoma).
- Conditions
- Cholangiocarcinoma, Gallbladder Carcinoma, Biliary Carcinoma
- Trial name
- NCT01855724
- Testing
- Gemcitabine-Pazopanib
- Where
- 17 sites in Greece
- Volunteers
- 29 people
- Sponsor
- Hellenic Cooperative Oncology Group
Hepatocellular Carcinoma, Primary Liver Cancer
Comprehensive Electronic Cancer Support System for the Treatment of Cancer Related Symptoms
The purpose of this study is to test the efficacy of a collaborative care intervention to manage cancer-related symptoms and improve health related quality of life in patients diagnosed with hepatobiliary carcinoma.
- Conditions
- Hepatocellular Carcinoma, Primary Liver Cancer, Bile Duct Cancer, Pancreatic Cancer
- Trial name
- CaSSY (NCT01640522)
- Testing
- Collaborative Care, Enhanced usual Care
- Where
- United States
- Volunteers
- 261 people
- Sponsor
- University of Pittsburgh
Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma
Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver Tumors
This is an Open-label, Phase 1b/2 Study of the Pressure-Enabled Hepatic Artery Infusion (HAI) of SD-101, a TLR9 agonist, Alone or in Combination with Intravenous Checkpoint Blockade in Adults with Hepatocellular Carcinoma (HCC)…
- Trial name
- NCT05220722
- Testing
- SD-101, Pembrolizumab, Nivolumab
- Where
- 4 sites in United States
- Volunteers
- 23 people
- Sponsor
- TriSalus Life Sciences, Inc.
Biliary Tract Cancer, HER2 Gene Mutation
Efficacy and Safety of GemCis Plus Trastuzumab Plus Pembrolizumab in Previously Untreated HER2-positive Biliary Tract Cancer
This is a multicenter, single arm, prospective, open-label phase II trial investigating the clinical activity triplet regimen consisting of a combination of chemotherapy (gemcitabine/cisplatin) + trastuzumab + pembrolizumab as…
- Conditions
- Biliary Tract Cancer, HER2 Gene Mutation, HER2
- Trial name
- TRAP-BTC (NCT06178445)
- Testing
- SOC plus trastuzumab and pembrolizumab
- Where
- 8 sites in Germany
- Volunteers
- 24 people
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
HER2-negative Breast Cancer, Gastric Adenocarcinoma
Niraparib Combined With Anlotinib in Homologous Recombination Repair (HRR) Gene-mutated Advanced Solid Tumors
Homologous Recombination Repair (HRR) gene mutations can be detected in many solid tumors, patients with HRR gene mutations may benefit from PARP inhibitor.
- Conditions
- HER2-negative Breast Cancer, Gastric Adenocarcinoma, Cholangiocarcinoma, Pancreatic Cancer
- Trial name
- NCT04764084
- Testing
- Niraparib, Anlotinib
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Peking University Cancer Hospital & Institute
Intrahepatic Cholangiocarcinoma
Chidamide Combined With Chemotherapy and Immunotherapy as First-line Treatment for Advanced Intrahepatic Cholangiocarcinoma
This is a single-center, open-label, phase II clinical trial designed to evaluate the efficacy and safety of chidamide in combination with chemotherapy and immunotherapy as a first-line treatment for patients with advanced…
- Trial name
- NCT07570849
- Testing
- Chidamide, Gemcitabine, cisplatin, immune checkpoint inhibitor
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Shanghai Zhongshan Hospital
Cholestasis, Icterus
FGF19 in Obstructive Cholestasis: "Unveil the Signal"
Rationale: Bile salts are potent signalling molecules influencing various metabolic and functional processes. Bile salts exert these functions by activating nuclear (e.g. FXR ) and plasma cell membrane-bound receptors (e.g.
- Conditions
- Cholestasis, Icterus, Cholangiocarcinoma, Pancreatic Neoplasms
- Trial name
- FOCUS (NCT05718349)
- Testing
- Biospecimen sampling
- Where
- Germany
- Volunteers
- 81 people
- Sponsor
- Nicole Hildebrand
Intrahepatic Cholangiocarcinoma, Combined Hepatocellular and Cholangiocarcinoma
Derazantinib in Subjects With FGFR2 Gene Fusion-, Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma
This Phase II, open-label, single-arm study evaluated the anti-cancer activity of derazantinib in subjects with inoperable or advanced intrahepatic cholangiocarcinoma (iCCA) who received at least one prior regimen of systemic…
- Trial name
- FIDES-01 (NCT03230318)
- Testing
- derazantinib
- Where
- 41 sites in United States, Belgium and 9 more
- Volunteers
- 148 people
- Sponsor
- Basilea Pharmaceutica
Advanced Cholangiocarcinoma
Lenvatinib, Tislelizumab Plus Gemcitabine and Cisplatin (GPLET) in Patients with Advanced Cholangiocarcinoma
Cholangiocarcinoma (CCA) is a heterogeneous group of cancers arising from the epithelial cells of bile ducts. Because of highly aggressive malignancy, most of the patients are diagnosed at an advanced stage and lose the chance to…
- Trial name
- NCT05532059
- Testing
- Lenvatinib, tislelizumab, gemcitabine and cisplatin, gemcitabine and cisplatin
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Biliary Tract Cancer (BTC)
D07001 Softgel-Capsules and Capecitabine Combination Therapy in Patients With Advanced Biliary Tract Cancer
The object of this trial is to evaluate the efficacy of D07001-softgel capsules + capecitabine compared with placebo + capecitabine by overall survival (OS).
- Trial name
- NCT06622057
- Testing
- D07001-Softgel Capsules, Capecitabine
- Where
- 4 sites in United States, Taiwan
- Volunteers
- 240 people
- Sponsor
- InnoPharmax Inc.
Advanced Bile Duct Carcinoma, Advanced Gallbladder Carcinoma
Trifluridine/Tipiracil and Irinotecan for the Treatment of Advanced Refractory Biliary Tract Cancer
This phase II trial studies how well trifluridine/tipiracil and irinotecan work in treating patients with biliary tract cancer that has spread to other places in the body (advanced) and has not responded to treatment…
- Conditions
- Advanced Bile Duct Carcinoma, Advanced Gallbladder Carcinoma, Refractory Bile Duct Carcinoma, Refractory Gallbladder Carcinoma
- Trial name
- NCT04072445
- Testing
- Irinotecan, Irinotecan Hydrochloride, Trifluridine and Tipiracil Hydrochloride
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Mayo Clinic
Cholangiocarcinoma
Phase 1 In-vivo Biliary Study of KSP/QRH Heptapeptide Dimer
The overall aim of this feasibility study is to develop new technologies for improved detection of cholangiocarcinoma using the SFE-based molecular-imaging mini-cholangioscope (MC) system.
- Trial name
- NCT04304781
- Testing
- KSP/QRH dimer
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Danielle Kim Turgeon
Pancreatic Cancer, Ampullary Cancer
Recurrence After Whipple's (RAW) Study
Pancreatic head malignancies are aggressive cancers that are often inoperable when they are diagnosed. In the ~20% of patients who are diagnosed when the disease is still operable, surgery is the only treatment that can provide a…
- Conditions
- Pancreatic Cancer, Ampullary Cancer, Bile Duct Cancer, Cholangiocarcinoma, Extrahepatic
- Trial name
- NCT04596865
- Testing
- Pancreaticoduodenectomy
- Where
- 29 sites in Australia, Austria and 6 more
- Volunteers
- 1,484 people
- Sponsor
- University Hospital Plymouth NHS Trust
Intrahepatic Cholangiocarcinoma
Routine Lymphadenectomy for Intrahepatic Cholangiocarcinoma
The role of routine lymphadenectomy (LND) in the surgical treatment of intrahepatic cholangiocarcinoma (ICC) remains controversial.
- Trial name
- LND for ICC (NCT03796819)
- Testing
- lymphadenectomy
- Where
- China
- Volunteers
- 260 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Biliary Tract Cancer
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
The purpose of this study is to evaluate the efficacy and safety of Zanidatamab plus CisGem (Cisplatin and Gemcitabine) with or without the addition of a programmed death protein 1/ligand-1 (PD-1/L1) inhibitor (physician's choice…
- Trial name
- NCT06282575
- Testing
- Zanidatamab, Cisplatin, Gemcitabine
- Where
- 185 sites in United States, Argentina and 23 more
- Volunteers
- 286 people
- Sponsor
- Jazz Pharmaceuticals
Intrahepatic Cholangiocarcinoma
Lenvatinib Plus Sintilimab in Patients With Immune Checkpoint Inhibitor Previously Treated Advanced Liver Cancer
The objective of this study is to evaluate the efficacy and safety of Lenvatinib plus Sintilimab in patients with advanced liver cancer progressed after treatment with immune checkpoint inhibitors.
- Trial name
- NCT05010681
- Testing
- Sintilimab, Lenvatinib
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Fudan University
Cholangiocarcinoma,Adult
Efficacy and Safety of 3D185 Monotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Cholangiocarcinoma
The purpose of this study is evaluate the efficacy of 3D185 in subjects with advanced/metastatic cholangiocarcinoma with FGFR2 Gene Alterations who have failed at least 1 previous treatment.
- Trial name
- NCT05039892
- Testing
- 3D185
- Volunteers
- 50 people
- Sponsor
- 3D Medicines (Beijing) Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.